LEADER 05190nam 2201333z- 450 001 9910566475103321 005 20231214133451.0 035 $a(CKB)5680000000037628 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/81151 035 $a(EXLCZ)995680000000037628 100 $a20202205d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aPersonalized Medicine in the Field of Inflammatory Skin Disorders 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 electronic resource (262 p.) 311 $a3-0365-3574-8 311 $a3-0365-3573-X 330 $aSkin inflammation is associated with a wide range of conditions which represent major health issues worldwide. Skin and mucosal surfaces represent the primary interface between the human body and the environment, susceptible to numerous factors whose action results in diseases produced by chemical substances, mechanical trauma, microbial agents, radiation, etc. Inflammation, a complex network of interactions between soluble molecules and cells, represents the main modality of the skin?s response to injuries. Numerous studies have revealed close links between chronic inflammation, oxidative stress, and carcinogenesis. Chronic inflammation induces the activation of various cell types and an increase in the production of reactive oxygen species, promoting the initiation of a malignant process. Identifying specific biomarkers is essential for understanding molecular mechanisms and developing therapies appropriate to the patient?s characteristics.Personalized medicine is an emerging field of medicine that has the potential to predict which therapy will be safe and efficacious for specific patients using an individual?s genetic profile to guide decisions regarding the diagnosis, treatment, as well as prevention of disease. This book gathers articles that present recent advancements in research involving the mechanisms that underlie the development of inflammatory skin disorders, skin and mucosal inflammation in general. 606 $aMedicine$2bicssc 610 $asea-buckthorn seed oil 610 $along-chain fatty acids 610 $askin dysplastic keratinocytes 610 $aUVA 610 $aCD36 610 $aSR-B2 610 $aatopic dermatitis 610 $aeczema 610 $aJAK inhibitors 610 $asystematic review 610 $ameta-analysis 610 $aevidence-based medicine 610 $aimmune-mediated skin diseases 610 $atarget therapy 610 $askin conditions and systemic inflammatory diseases 610 $asystemic sclerosis 610 $abiomarker 610 $acalumenin 610 $aS100A6 610 $acytohesin 2 610 $acannabinoids 610 $ainflammation 610 $agut-lung-skin barrier 610 $asignaling pathways 610 $ainflammatory biomarkers 610 $apsoriasis vulgaris 610 $aprevalence 610 $acomorbidities 610 $arisk factors 610 $asystemic lupus erythematous 610 $alupus nephritis 610 $alipid peroxidation 610 $aDNA oxidation 610 $aoxidized proteins 610 $acarbohydrate oxidation 610 $aantioxidative stress strategies 610 $abiomarkers 610 $aIgY 610 $apsoriatic dermatitis 610 $aimiquimod 610 $aC57 BL/6 mice 610 $aalginate 610 $abiomaterial 610 $adressing 610 $afibers 610 $ahydrogel 610 $ananofibers 610 $acommercially available 610 $awound care 610 $awound healing 610 $acutaneous melanoma 610 $aepigenetic regulation 610 $adrug resistance 610 $atherapeutic targets 610 $aepigenetic therapy 610 $aimmune response 610 $aSutton nevi 610 $ahalo nevi 610 $askin tumor 610 $apsoriasis 610 $aproteome analysis 610 $aestrogen 610 $amenopause 610 $acSCC 610 $aAK 610 $asialylation 610 $asialyltransferase 610 $asialidase 610 $aCOVID-19 610 $apyoderma gangrenosum 610 $aimmunosuppression 610 $acyclosporine 610 $acorticosteroids 610 $aautoinflammatory disease 610 $aandrogenic alopecia 610 $aclinical trial 610 $ahair density 610 $aplatelet-rich plasma 615 7$aMedicine 700 $aTampa$b Mircea$4edt$01279506 702 $aNeagu$b Monica$4edt 702 $aCaruntu$b Constantin$4edt 702 $aGeorgescu$b Simona Roxana$4edt 702 $aTampa$b Mircea$4oth 702 $aNeagu$b Monica$4oth 702 $aCaruntu$b Constantin$4oth 702 $aGeorgescu$b Simona Roxana$4oth 906 $aBOOK 912 $a9910566475103321 996 $aPersonalized Medicine in the Field of Inflammatory Skin Disorders$93015522 997 $aUNINA